Re: ER today
I am traveling so I didnít get the chance to listen to CC. While I donít like the idea of monetizing Inclisiran, value of Inclisiran is not currently reflected in the current price of ALNY. MDCO has a market cap of $4B based on just one drug Inclisiran. I think ALNY interest in Inclisiran is at least worth $3B considering it gets up to 20% royalty from Inclisiran that goes straight to its bottom line. If company can get $3B+ for it, it is worth considering it. Cash can be used to to develop other more potent drugs.